PQ 1522
1522. Deputy Paul Murphy asked the Minister for Health if the National Gender Service is aware of EMA/147755/2020 "restrictions in use of cyproterone due to meningioma risk" and the 2021 paper "Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study"; and what initial dose they use for cyproterone acetate. [14906/24]
Introduced
9 April 2024
Last action
—
Status
written
Sponsors
—
Subjects
Discovery layer
Source updated
9 April 2024
Summary
1522. Deputy Paul Murphy asked the Minister for Health if the National Gender Service is aware of EMA/147755/2020 "restrictions in use of cyproterone due to meningioma risk" and the 2021 paper "Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study"; and what initial dose they use for cyproterone acetate. [14906/24]
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
1 official file
Health Services
Health Services
xml · EN · 9 April 2024
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.oireachtas.ie/en/debates/question/2024-04-09/1522/
- Open data entity: https://data.oireachtas.ie/ie/oireachtas/question/2024-04-09/pq_1522